Overview

Study to Evaluate Safety and Tolerability of ACT-709478 in Healthy Subjects

Status:
Completed
Trial end date:
2018-12-28
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the safety and tolerability of ascending multiple doses of ACT-709478 in healthy male and female subjects
Phase:
Phase 1
Details
Lead Sponsor:
Actelion
Idorsia Pharmaceuticals Ltd.
Treatments:
ACT-709478
Midazolam